[go: up one dir, main page]

WO2008033395A3 - Melanocortin and transferrin fusion proteins - Google Patents

Melanocortin and transferrin fusion proteins Download PDF

Info

Publication number
WO2008033395A3
WO2008033395A3 PCT/US2007/019809 US2007019809W WO2008033395A3 WO 2008033395 A3 WO2008033395 A3 WO 2008033395A3 US 2007019809 W US2007019809 W US 2007019809W WO 2008033395 A3 WO2008033395 A3 WO 2008033395A3
Authority
WO
WIPO (PCT)
Prior art keywords
melanocortin
transferrin
moiety
fusion proteins
transferrin fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019809
Other languages
French (fr)
Other versions
WO2008033395A2 (en
Inventor
Homayoun Sadeghi
Christopher Philip Prior
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorexis Pharmaceutical Corp
Original Assignee
Biorexis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp
Publication of WO2008033395A2 publication Critical patent/WO2008033395A2/en
Publication of WO2008033395A3 publication Critical patent/WO2008033395A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses fusion proteins comprising a transferrin moiety and a melanocortin or melanocortin receptor agonist moiety. In one embodiment of the invention, the transferrin moiety is modified to exhibit reduced or no glycosylation. In another embodiment, the transferrin moiety is modified to exhibit reduced or no binding to a transferrin receptor. The fusion protein of the invention can optionally comprise a linker peptide and/or a second therapeutic peptide such as GLP-1 or exendin-4. Also disclosed are methods of treating or preventing a disease or condition in a subject by administering a fusion protein of the invention.
PCT/US2007/019809 2006-09-14 2007-09-11 Melanocortin and transferrin fusion proteins Ceased WO2008033395A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84434806P 2006-09-14 2006-09-14
US60/844,348 2006-09-14

Publications (2)

Publication Number Publication Date
WO2008033395A2 WO2008033395A2 (en) 2008-03-20
WO2008033395A3 true WO2008033395A3 (en) 2008-05-15

Family

ID=39125184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019809 Ceased WO2008033395A2 (en) 2006-09-14 2007-09-11 Melanocortin and transferrin fusion proteins

Country Status (1)

Country Link
WO (1) WO2008033395A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611323B2 (en) 2010-11-30 2017-04-04 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2259794A1 (en) * 2008-02-22 2010-12-15 Clinuvel Pharmaceuticals Limited Method for treatment of photosensitivity and phototoxicity
WO2009147180A2 (en) * 2008-06-05 2009-12-10 Basf Se Microbicidal peptides of trichoderma reesei
DK3252068T3 (en) 2009-10-12 2025-08-25 Larry J Smith METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING OLIGONUCLEOTIDE-BASED DRUGS ADMINISTERED IN VIVO OR IN VITRO
EP2968475A2 (en) 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
WO2015162486A1 (en) * 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
WO2016069889A1 (en) * 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
EP3373947B1 (en) 2015-11-09 2022-03-02 Trustees Of Tufts College Compounds and methods for treating pain
US10774127B2 (en) 2016-10-12 2020-09-15 University Of Copenhagen Peptide dual agonists of GIPR and GLP2R
CN107573414B (en) * 2017-08-14 2020-08-07 李翀 Human bladder cancer marker AG-CD71 and its antibody ABC71 and its application
US11753455B2 (en) 2018-06-21 2023-09-12 Novo Nordisk A/S Compounds for treatment of obesity
TWI861780B (en) * 2022-03-28 2024-11-11 南韓商Ｌｇ化學股份有限公司 Combination therapy for preventing or treating obesity
WO2025123056A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and associated methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020588A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
WO2004019872A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
WO2006017688A2 (en) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Combination therapy using transferrin fusion proteins comprising glp-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020588A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
WO2004019872A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
WO2006017688A2 (en) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Combination therapy using transferrin fusion proteins comprising glp-1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 27 January 2005 (2005-01-27), "Human transferrin protein.", XP002471765, retrieved from EBI accession no. GSP:ADU17611 Database accession no. ADU17611 *
MATSUBARA MUNEAKI ET AL: "Glucagon-like-peptide-1 fused to transferrin: A novel approach to myocardial reperfusion injury", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 49, no. 9, Suppl. A, March 2007 (2007-03-01), & 56TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-COLLEGE-OF-CARDIOLOGY; NEW ORLEANS, LA, USA; MARCH 24 -27, 2007, pages 236A, XP009096973, ISSN: 0735-1097 *
MUNEAKI MATSUBARA, EARL ALBONE, JOSEPH H. GORMAN AND ROBERT C. GORMAN: "?-Melanocyte Stimulating Hormone Fused to Transferrin: A Novel Adjunct to Reperfusion Therapy for Acute MI", CARDIOVASCULAR PHYSIOLOGY, 1 August 2007 (2007-08-01), pages S92, XP002471736 *
RAFFIN-SANSON M L ET AL: "Proopiomelanocortin, a polypeptide precursor with multiple functions: From physiology to pathological conditions.", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 149, no. 2, August 2003 (2003-08-01), pages 79 - 90, XP002471746, ISSN: 0804-4643 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611323B2 (en) 2010-11-30 2017-04-04 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
US10941215B2 (en) 2010-11-30 2021-03-09 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses thereof

Also Published As

Publication number Publication date
WO2008033395A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008033395A3 (en) Melanocortin and transferrin fusion proteins
WO2006024275A3 (en) Glp-1 and exendin related invention
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2007047834A3 (en) Oral peptide conjugates for metabolic diseases
GEP20146112B (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof
WO2009133137A3 (en) Pegylated recombinant human growth hormone compounds
WO2008143954A3 (en) Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2008066752A8 (en) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
NZ585131A (en) Use melanocortins to treat insulin sensitivity
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
WO2007070671A3 (en) Therapeutic methods for inhibiting tumor growth with dll4 antagonists
WO2006017688A3 (en) Combination therapy using transferrin fusion proteins comprising glp-1
WO2008113515A3 (en) huTNFR1 SELECTIVE ANTAGONISTS
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
MY192113A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2007028394A3 (en) Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
WO2009025867A3 (en) Compositions of humanized notch fusion proteins and methods of treatment
WO2006087637A3 (en) Anti her2/neu antibody
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2007067596A3 (en) Methods and compositions for needleless delivery of antibodies
WO2006036877A3 (en) Recombinant bifunctional protein of human lutropin receptor and human chorionic gonadotropin b-subunit and uses thereof
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2009025300A1 (en) Peptide capable of binding to immunoglobulin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838084

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838084

Country of ref document: EP

Kind code of ref document: A2